CIK 0001737287
- Non-accelerated filer
- Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823562771
- Phone
- +1 650-457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 4 Open-market sale Director sold 10,000 shares at $11.76 ($117,600)
- 4 Open-market sale EVP of R&D and CMO sold 2,000 shares at $11.18 ($22,360)
- 4 Grant or award Director acquired 44,178 shares (grant or award)
- 4 Grant or award Director acquired 22,089 shares (grant or award)
- 4 Grant or award Director acquired 44,178 shares (grant or award)
- 4 Grant or award Director acquired 22,089 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale EVP of R&D and CMO sold 11,500 shares at $7.40 ($85,092)
- 4 Other disposition 10% owner disposed of 22,032,040 shares (other)
- 4/A Other disposition Director disposed of 4,710,120 shares (other)
- 4 Other disposition Director disposed of 4,710,121 shares (other)
- 4 Grant or award EVP of R&D and CMO acquired 237,358 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Grant or award Chief Financial Officer acquired 237,358 shares (grant or award)
- 4 Grant or award General Counsel acquired 175,438 shares (grant or award)
- 4 Open-market sale EVP of R&D and CMO sold 5,169 shares at $7.71 ($39,848)
- 4 Open-market sale General Counsel sold 8,849 shares at $7.68 ($67,962)
Page 7 of 14 · 275 filings